Evidence map›Paper›PMID 37729193›Full record

ArticlePloS one2023

Clinical and financial outcomes of hospitalizations for cardiac device infection during the COVID-19 pandemic in the US.

Nameer Ascandar, Nikhil Chervu, Syed Shahyan Bakhtiyar, Nam Yong Cho, Shineui Kim, Manuel Orellana, Peyman Benharash

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nameer AscandarCardiovascular Outcomes Research Laboratories (CORELab), David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Nikhil ChervuCardiovascular Outcomes Research Laboratories (CORELab), David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.ORCID 0000-0003-0327-9847
Syed Shahyan BakhtiyarCardiovascular Outcomes Research Laboratories (CORELab), David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Nam Yong ChoCardiovascular Outcomes Research Laboratories (CORELab), David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Shineui KimCardiovascular Outcomes Research Laboratories (CORELab), David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.ORCID 0000-0002-8174-8963
Manuel OrellanaCardiovascular Outcomes Research Laboratories (CORELab), David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Peyman BenharashCardiovascular Outcomes Research Laboratories (CORELab), David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.ORCID 0000-0002-4705-0262
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiac device infection (CDI) can occur in up to 2.2% of patients after device placement, with mortality rates exceeding 15%. Although device removal is standard management, the COVID-19 pandemic has been associated with resource diversion and decreased patient presentation for cardiovascular disease. We ascertained the association of the COVID-19 pandemic with outcomes and resource utilization after admission for CDI.

methodsThe 2016-2020 National Inpatient Sample was used to retrospectively study all adult admissions for CDI. Patients admitted between March and December, 2020 were classified as the pandemic cohort, with the rest pre-pandemic. The primary outcome was major adverse events (MAE), with secondary outcomes of overall length of stay (LOS), post-device removal LOS, time to device replacement, and hospitalization costs. MAE was a combination of in-hospital mortality and select complications. Multivariable regression models were developed to determine the relationship between the pandemic and the aforementioned outcomes.

resultsOf an estimated 190,160 patients, 14.3% comprised the pandemic cohort; 2.4% of these patients were COVID-19 positive. The pandemic cohort was older, less commonly female, and had higher rates of congestive heart failure. After adjustment, the pandemic was not associated with altered odds of MAE, device removal, or subsequent device replacement. The pandemic was, however, associated with decreased adjusted overall LOS (β -0.38 days) and days to device replacement (β -0.83 days). The pandemic was likewise associated with $2,000 increased adjusted hospitalization costs.

conclusionThe pandemic did not have a significant impact on clinical outcomes in patients admitted for CDI, despite higher hospitalization costs and decreased length of stay.

Indexed as

Communicable DiseasesCOVID-19Defibrillators, ImplantableHeart DiseasesAdultFemaleHospitalizationHumansPandemicsRetrospective Studies

Identifiers

PMID37729193
PMCPMC10511080
OpenAlexW4386884296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.